# Yttrium Y 90 Glass Microspheres and Capecitabine in Treating Patients With Liver Cholangiocarcinoma or Liver Metastases

Source: https://onco.cc/trials/nct00858429/  
OnCo record `nct00858429` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of Capecitabine and Doxifluridine in Hepatocellular carcinoma and Metastatic cancer, run by Northwestern University, completed.

## Summary

Yttrium Y 90 Glass Microspheres and Capecitabine in Treating Patients With Liver Cholangiocarcinoma or Liver Metastases is a phase 1 interventional study registered as NCT00858429 by Northwestern University, with 18 participants recorded, started 2009-04-01 and reaching its primary completion in 2014-03-19. Interventions recorded: capecitabine, yttrium Y 90 glass microspheres. Conditions recorded: Liver Cancer, Metastatic Cancer.

Linked to the drug Doxifluridine because the registry names it among its interventions and Hepatocellular carcinoma and Metastatic cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00858429
- Phase: 1
- Setting: Dose Escalating Study of Yttrium 90 Microspheres (TheraSphere) With Capecitabine (Xeloda) for Intrahepatic Cholangiocarcinoma or Metastatic Disease to the Liver
- Sponsor: Northwestern University
- Enrolled: 18

## Sources

- ClinicalTrials.gov NCT00858429: https://clinicaltrials.gov/study/NCT00858429

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [Doxifluridine](https://onco.cc/drugs/doxifluridine/)

---
JSON: https://onco.cc/api/v1/entities/nct00858429.json